The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The approval is supported by data from three pivotal clinical trials
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
Subscribe To Our Newsletter & Stay Updated
